Assessing and mitigating the interference of ALX148, a novel CD47 blocking agent, in pretransfusion compatibility testing.
Tae Yeul KimMi Sook YoonHein HustinxJanet SimHong I WanHyungsuk KimPublished in: Transfusion (2020)
ALX148 generates false-positive reactivity in IAT, interfering with pretransfusion compatibility testing. The use of soluble CD47 or high-affinity SIRPα monomers can resolve the interference without possibly missing clinically significant alloantibodies.
Keyphrases